Filing Details
- Accession Number:
- 0001209191-18-043879
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-07-25 16:06:34
- Reporting Period:
- 2018-07-23
- Accepted Time:
- 2018-07-25 16:06:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1358762 | Reata Pharmaceuticals Inc | RETA | Pharmaceutical Preparations (2834) | 113651945 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1662520 | Elaine Castellanos | 2801 Gateway Drive Suite 150 Irving TX 75063 | Principal Accounting Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Disposition | 2018-07-23 | 7,196 | $50.80 | 140 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2018-07-23 | 140 | $51.48 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2016 and amended on September 15, 2017.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $50.33 to $51.31. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $51.45 to $51.485. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Billionaire Hedge Funds
